gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Ankyrin repeat domain 30A

NY-BR-1, ANKRD30A, breast cancer antigen NY-BR-1, NY-BR-7
Sponsored links
Top mentioned proteins: CAN, Mammaglobin, cytokeratin, erbB-2, SET
Papers on NY-BR-1
Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
Müller-Tidow et al., Münster, Germany. In Clin Cancer Res, Dec 2015
We identified several recurrently mutated genes at low frequency (ANKRD30A, CCDC19, KIAA0319, KIAA1522, LAMB4, SLFN11, STAG2, TP53, UNC80, ZNF98).
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.
Hakonarson et al., Philadelphia, United States. In Nat Med, Sep 2015
We identified 27 genome-wide significant loci associated with one or more pAIDs, mapping to in silico-replicated autoimmune-associated genes (including IL2RA) and new candidate loci with established immunoregulatory functions such as ADGRL2, TENM3, ANKRD30A, ADCY7 and CD40LG.
Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.
Eichmüller et al., Heidelberg, Germany. In Int J Cancer, Jul 2015
The differentiation antigen NY-BR-1 appears overexpressed in invasive mammary carcinomas compared to healthy breast tissue, thus representing a promising target antigen for T cell based tumor immunotherapy approaches.
Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status.
Bhargava et al., Pittsburgh, United States. In Appl Immunohistochem Mol Morphol, Mar 2015
The individual marker positivity in decreasing order was 95% (177/186) for GATA-3, 92% (172/186) for cytokeratin (CK)7, 80% (151/189) for AR, 80% for estrogen receptor (158/198), 69% for progesterone receptor (137/198), 55% (105/190) for NY-BR-1, 52% (99/189) for mammaglobin, 31% (59/191) for vimentin, 26% (51/195) for GCDFP-15, 0.5% (1/186) for CK20, and 0% (0/188) for PAX-8.
NY-BR-1 Antigen Expression and anti-NY-BR-1 IgG in Egyptian Breast Cancer Patients: Clinicopathological and Prognostic Significance.
Abouelella et al., In Egypt J Immunol, 2014
NY-BR-1 antigen has been shown to be frequently expressed in breast cancers.
Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer.
Liu et al., Chongqing, China. In Cancer Biol Ther, 2014
ANKRD30A, a potential target for breast cancer immunotherapy, is currently one of the most used DTC markers.
Evolutionary distance of amino acid sequence orthologs across macaque subspecies: identifying candidate genes for SIV resistance in Chinese rhesus macaques.
Smith et al., Davis, United States. In Plos One, 2014
Additionally, ANKRD30A, CTSZ, GORASP2, GTF2H1, IL13RA1, MUC16, NMDAR1, Notch1, NT5M, PDCD5, RAD50, and TM9SF2 were identified as possible candidates, among others.
Positive selection of primate genes that promote HIV-1 replication.
Sawyer et al., Austin, United States. In Virology, 2014
Some of these genes (CD4, NUP153, RANBP2/NUP358) have been characterized with respect to the HIV lifecycle, while others (ANKRD30A/NY-BR-1 and MAP4) remain relatively uncharacterized.
Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.
Wei et al., Tianjin, China. In Nat Commun, 2013
(rs1192691 near ANKRD30A, P(meta) = 2.62 × 10(-8)), and two consistently replicated loci at 12q14.2 (rs11175194 in SRGAP1, P(meta) = 1.14 × 10(-7)) and 9q34.2 (rs633862 near ABO and SURF6, P(meta) = 8.57 × 10(-7)) (P<0.05 in all three stages).
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications.
Stickeler et al., Freiburg, Germany. In Bmc Cancer, 2012
The breast differentiation antigen NY-BR-1, expressed specifically in normal and malignant breast tissue, has also immunogenic properties.
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts.
Moch et al., Zürich, Switzerland. In Int J Cancer, 2008
We identified estrogen-response element (ERE)-like sequences nearby the NY-BR-1 promoter region, suggesting that NY-BR-1 expression might be regulated through estrogen receptors.
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
Jäger et al., Frankfurt am Main, Germany. In Int J Cancer, 2007
The strong expression of NY-BR-1 in breast tumors, its cytoplasmic and membrane localization and accessibility to an ectopically applied antibody now suggest to pursue NY-BR-1 as a potential target for antibody-based therapies in breast cancer patients.
NY-BR-1 is a differentiation antigen of the mammary gland.
Jungbluth et al., Heidelberg, Germany. In Appl Immunohistochem Mol Morphol, 2007
testing demonstrates NY-BR-1 in a mostly focal fashion in the epithelia of ducts and acini of the mammary gland. In tumors, homogenous staining can be seen in almost all ductal carcinomas in situ and/or the intraductal component of invasive carcinomas.
Significance, detection and markers of disseminated breast cancer cells.
Lacroix, Brussels, Belgium. In Endocr Relat Cancer, 2006
DTC markers are listed and the most currently used of them (KRT19, CEACAM5, TACSTD1, MUC1, EGFR, ERBB2, SCGB2A2, SCGB2A1, SCGB1D2, PIP, SBEM, TFF1, TFF3, ANKRD30A, SPDEF, ESR1, SERPINB5 and GABRP) are discussed, notably on the basis of recent data on breast tumour portraits (luminal epithelial-like, basal/myoepithelial-like and ERBB2).
Potential target antigens for immunotherapy identified by serological expression cloning (SEREX).
Jäger, Heidelberg, Germany. In Methods Mol Biol, 2006
We recently identified a new breast cancer differentiation antigen designated as NY-BR-1 in an autologous breast cancer SEREX screening.
Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases.
Moch et al., Zürich, Switzerland. In Clin Cancer Res, 2006
NY-BR-1 is a differentiation antigen of the breast, which is present in normal and tumorous mammary epithelium.
Antibodies and vaccines--hope or illusion?
Knuth et al., Zürich, Switzerland. In Breast, 2005
Another new cancer antigen explored for cancer vaccination is the breast differentiation antigen NY-BR-1, expressed in 70% of all tested primary breast cancers.
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.
Jäger et al., Heidelberg, Germany. In Cancer Immun, 2004
In this study we extended the expression analysis to various other normal and tumor tissues and found inconsistent expression of NY-BR-1 in normal prostate, but consistent NY-BR-1 mRNA expression in 32% of prostate cancers, but not in other tumor types
Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning.
Knuth et al., Zürich, Switzerland. In Cancer Immunol Immunother, 2004
This article summarizes our approach of antigen identification and evaluation giving the example of the recently cloned breast cancer antigen NY-BR-1.
share on facebooktweetadd +1mail to friends